Module 3 of 5

Drug vs supplement vs research chemical

Three legal buckets get confused all the time. Walk through how US federal law actually sorts a peptide, why most peptides are not dietary supplements, and why "not a controlled substance" is not the same as "legal to sell".

Read this first. This page is educational only and is not legal advice. It describes US federal law and regulatory positions as of June 2026, a fast-moving area where rules change often. State law can differ and may be stricter. Nothing here tells you how to buy, import, or use anything; it only explains how the rules are organized. For your own situation, consult a licensed attorney.

The three buckets people confuse

Most "is this peptide legal?" arguments fall apart because people are quietly using three different definitions at once. A product can sit in a surprising bucket, or fall outside all three of the friendly ones. Here is the map.

The key move. "Approved drug" and "dietary supplement" are real legal categories with real rules. "Research chemical" is a label, not a category. When a product is not an approved drug and does not fit the supplement definition, the practical question becomes the one in the next sections: is it an unapproved new drug?

Why peptides rarely fit "dietary supplement"

The word "supplement" has a precise legal meaning set by a 1994 law called DSHEA (the Dietary Supplement Health and Education Act). It does two things that matter here: it defines what a supplement is, and it excludes certain articles outright.

Two hurdles, not one. A peptide has to clear both the definition and the exclusion to be a supplement. An amino acid (a single building block) can qualify as a dietary ingredient; a built, free-standing peptide chain marketed for an effect on the body usually does not. Note: the FDA's reading of "dietary ingredient" is actively contested, so treat this as the picture as of June 2026.

The FDA's position: unapproved new drugs

If a peptide is not an approved drug and does not fit the supplement definition, where does it land? The FDA's stated position is that injectable and "research" peptides sold for human use are typically unapproved new drugs and misbranded drugs. This is the agency's position, not a verdict that "all peptides are illegal".

Intended use, not the name

how the FDA decides

Whether something is a "drug" turns on its intended use, which the FDA infers from the seller's website and marketing, not from the product name or a disclaimer. If the surrounding messaging points to human use, the agency can treat the product as a drug.

Disclaimers do not exempt

"research use only" / "not for human consumption"

In warning letters, the FDA's standard line is that "research use only" and "not for human consumption" labels do not shield products from enforcement when the evidence shows the products are intended for human use. The label is treated as a framing, not a legal status.

What "unapproved new drug" actually means. It is a marketing-authorization statement: the FDA has not reviewed the product for safety, effectiveness, or quality before sale. Federal law (21 U.S.C. 355(a)) bars introducing a new drug into interstate commerce without an effective approval, and a "misbranded" drug is one whose labeling is false or misleading. Both are framed around selling, which leads to the next two sections.

"Not a controlled substance" is not "legal to sell"

A very common mix-up: people check whether a peptide is a DEA-scheduled controlled substance, find that it is not, and conclude it is "legal". But drug scheduling and drug approval are two completely separate legal systems.

One important exception: human growth hormone. A separate federal statute, 21 U.S.C. 333(e), makes it a crime to distribute, or possess with intent to distribute, human growth hormone (somatrem, somatropin, or an analogue) for uses in humans not authorized by the Secretary and ordered by a physician. Growth-hormone-releasing peptides and secretagogues are generally unscheduled, but whether a specific one counts as an "analogue" of HGH is a fact-specific, unsettled legal question. Do not over-extend this exception to all peptides.

Who bears the legal risk?

The federal prohibited acts are written around the act of putting a product into the market. That design matters for understanding where the exposure sits. This is a description of how the statute is structured, not advice about anyone's situation.

Why this distinction is taught carefully. "The seller carries the main federal drug-marketing risk" is a statement about how the statute is built, not reassurance that buying is consequence-free. Other rules cover importation, sport, and the workplace, and they are covered in the next modules of this course.

Common questions

Short, neutral answers to the questions people ask most about how peptides are classified. All of this is general education, not legal advice, and reflects US federal law as of June 2026.

Are peptides classified as dietary supplements?

Usually not. DSHEA defines a supplement narrowly (vitamin, mineral, herb, amino acid, and similar), and a free-standing synthetic peptide generally does not fit unless it is already part of the food supply. A separate exclusionary clause can also block any article studied as a drug before it was sold as a supplement.

Does a "research use only" label make a peptide legal to sell?

No. The FDA's position is that intended use is read from the seller's marketing, not from a disclaimer. It has treated "research" peptides sold for human use as unapproved new drugs, and states that such labels do not shield a product from enforcement.

Are peptides controlled substances?

Most are not DEA-scheduled. The Controlled Substances Act is separate from FDA approval law, so "not a controlled substance" does not mean "legal to sell". One exception: 21 U.S.C. 333(e) criminalizes non-authorized human growth hormone distribution, and the "analogue" question for GH-releasing peptides is unsettled.

Who bears the legal risk, the buyer or the seller?

The federal prohibited acts target introducing a drug into commerce, a distribution act, so the main exposure sits with the seller or distributor. Federal drug law does not make mere personal possession of a non-controlled, unapproved drug a federal offense, but state law and other regimes can still apply.

  1. Dietary Supplement Health and Education Act of 1994 (DSHEA), amending FD&C Act § 201(ff) (21 U.S.C. § 321(ff)); dietary supplement definition. NIH Office of Dietary Supplements, "DSHEA Wording." ods.od.nih.gov
  2. FD&C Act § 201(ff)(3)(B) (21 U.S.C. § 321(ff)(3)(B)); exclusionary clause for prior drug approval or investigation. law.cornell.edu/uscode/text/21/321
  3. FD&C Act § 505(a) (21 U.S.C. § 355(a)); no new drug may enter interstate commerce without an effective approval. law.cornell.edu/uscode/text/21/355
  4. FD&C Act § 301(a),(d) (21 U.S.C. § 331(a),(d)); prohibited acts targeting introduction of unapproved or misbranded articles into interstate commerce. law.cornell.edu/uscode/text/21/331
  5. Controlled Substances Act, 21 U.S.C. § 812 (schedules); a regime distinct from FD&C Act drug approval. law.cornell.edu/uscode/text/21/812
  6. FD&C Act § 303(e) (21 U.S.C. § 333(e)), "Prohibited distribution of human growth hormone." govinfo.gov. govinfo.gov
  7. FDA Warning Letter, US Chem Labs (#669074, Feb. 7, 2024); "research use only" / "not for human consumption" peptides treated as unapproved new drugs and misbranded. fda.gov

Knowledge check

Test what you learned in this module.

Practice exercises

Reinforce your understanding with interactive exercises.

Next module

Sport, anti-doping & work